Catalogue Number	Product	Order number / Unit

9715 DOTA-[Pro^1,Tyr^4]bombesin (1-14)

9715.0001: 1 mg per vial
9715.0010: 10 mg per vial
Please inquire for customized filling and bulk quantities.



DOTA-[Pro^1,Tyr^4]bombesin (1-14) trifluoroacetate

DOTA-Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH_2

Precursor for radiolabelled DOTA-[Pro^1,Tyr^4] bombesin (1-14)

Molar Mass: 2042.28

$C_{90}H_{136}N_{28}O_{25}S$

[593287-40-2] (net peptide)

Colourless to off-white freeze-dried solid packaged in dark glass screw cap vials.

Purity: ≥ 95 %

Certificates:
CoA; MS (identity) and HPLC (purity)

Chemical Name:
CA index name: Bombesin, 1-[1-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-proline]-4-L-tyrosine-

Synonymes:
Bombesin, 1-[1-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl] acetyl]-L-proline]-4-L-tyrosine-; MP2346; DOTA-[P^1, Y^4]BBN(1-14)

Literature:

1. Biddlecombe G.B. et al. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using ^{64}Cu- and ^{86}Y-DOTA-[Pro^1,Tyr^4]-bombesin(1-14). Bioconjug Chem. 2007, 18, 724-30.

2. Breeman W.A. et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 1999, 81, 658-65.

3. Breeman W.A. et al. Preclinical comparison of 111In-labeled DTPA- or DOTA-bombesin analogs for receptor targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 2002, 43, 1650-56.

date of product catalogue issue: 05 April 2012